Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study
Background/Aims: Severe involvement of central and/or peripheral nervous system is a rare complication of hepatitis C virus (HCV)‐related cryoglobulinaemia. Method: Four patients with HCV‐related type II/III cryoglobulinaemia (three males with genotype 1, one female with genotype 3) who presented wi...
Gespeichert in:
| Veröffentlicht in: | Liver international 2007-04, Vol.27 (3), p.414-420 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 420 |
|---|---|
| container_issue | 3 |
| container_start_page | 414 |
| container_title | Liver international |
| container_volume | 27 |
| creator | Koskinas, J. Kilidireas, C. Karandreas, N. Kountouras, D. Savvas, S. Hadziyannis, E. Archimandritis, A.J. |
| description | Background/Aims: Severe involvement of central and/or peripheral nervous system is a rare complication of hepatitis C virus (HCV)‐related cryoglobulinaemia.
Method: Four patients with HCV‐related type II/III cryoglobulinaemia (three males with genotype 1, one female with genotype 3) who presented with severe sensory–motor polyneuropathy, one with central nervous system involvement as well, were treated with pegylated IFNa‐2b 1.5 μg/kg/week and ribavirin 10.6 mg/kg/daily for 48 weeks. Neurological evaluation involved detailed clinical motor and sensory scores/scales and neurophysiological studies before and after treatment.
Results/Conclusion: Three out of four patients had undetectable serum HCV‐RNA, normal levels of aminotransferases and substantially lower or undetectable levels of cryoglobulins at the end of treatment and at 24 weeks follow‐up period. Treatment was well tolerated and all patients exhibited significant improvement of neuropathy based on solid clinical and laboratory criteria that was associated with the virological response. |
| doi_str_mv | 10.1111/j.1478-3231.2006.01436.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70263519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70263519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3676-544d0cb20ee2ebdf568a7c0672daa461b0e70e1b73300cd65f7138d703aa80733</originalsourceid><addsrcrecordid>eNqNkc1u1DAURiMEoqXwCsgrVkyw48TOILFAI6CVRmLBz9ZynJsZj5w42E5b7_oISLxOn6ZPgjMZlS3e-Mo-37mLL8sQwTlJ590hJyWvV7SgJC8wZjkmJWX57ZPs_PHj6eNc0LPshfcHjMl6XZHn2RnhtKpKVp1n99_gGhygPYwy6KA92qBr7Sb_cPfbgZEBWqRctDtjm8noQUKvFfIweOviw92f3gbr0GhNHGByNkn2EQUHx-CNDns0wi4uHj0EcB04OyS5LBokhxY53ci0UA_vkUp-raR5i4xsrJPJHI_Mot5Hr62xuxlBPkxtfJk966Tx8Op0X2Q_Pn_6vrlcbb9-udp83K4UZZytqrJssWoKDFBA03YVqyVXmPGilbJkpMHAMZCGU4qxalnVcULrlmMqZY3T60X2ZvGOzv6awAfRa6_AGDmAnbzguGC0IusE1guonPXeQSdGp3vpoiBYzM2Jg5hLEXNBYm5OHJsTtyn6-rRjanpo_wVPVSXgwwLcaAPxv8Vie_VznuhfinexAg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70263519</pqid></control><display><type>article</type><title>Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Koskinas, J. ; Kilidireas, C. ; Karandreas, N. ; Kountouras, D. ; Savvas, S. ; Hadziyannis, E. ; Archimandritis, A.J.</creator><creatorcontrib>Koskinas, J. ; Kilidireas, C. ; Karandreas, N. ; Kountouras, D. ; Savvas, S. ; Hadziyannis, E. ; Archimandritis, A.J.</creatorcontrib><description>Background/Aims: Severe involvement of central and/or peripheral nervous system is a rare complication of hepatitis C virus (HCV)‐related cryoglobulinaemia.
Method: Four patients with HCV‐related type II/III cryoglobulinaemia (three males with genotype 1, one female with genotype 3) who presented with severe sensory–motor polyneuropathy, one with central nervous system involvement as well, were treated with pegylated IFNa‐2b 1.5 μg/kg/week and ribavirin 10.6 mg/kg/daily for 48 weeks. Neurological evaluation involved detailed clinical motor and sensory scores/scales and neurophysiological studies before and after treatment.
Results/Conclusion: Three out of four patients had undetectable serum HCV‐RNA, normal levels of aminotransferases and substantially lower or undetectable levels of cryoglobulins at the end of treatment and at 24 weeks follow‐up period. Treatment was well tolerated and all patients exhibited significant improvement of neuropathy based on solid clinical and laboratory criteria that was associated with the virological response.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/j.1478-3231.2006.01436.x</identifier><identifier>PMID: 17355465</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Antiviral Agents - administration & dosage ; Central Nervous System Diseases - virology ; cryoglobulinaemia ; Cryoglobulinemia - virology ; Drug Therapy, Combination ; Female ; HCV ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Humans ; Interferon-alpha - administration & dosage ; Male ; Middle Aged ; pegylated interferon ; peripheral neuropathy ; Polyethylene Glycols ; Polyneuropathies - diagnosis ; Polyneuropathies - virology ; Recombinant Proteins ; ribavirin ; Ribavirin - administration & dosage</subject><ispartof>Liver international, 2007-04, Vol.27 (3), p.414-420</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3676-544d0cb20ee2ebdf568a7c0672daa461b0e70e1b73300cd65f7138d703aa80733</citedby><cites>FETCH-LOGICAL-c3676-544d0cb20ee2ebdf568a7c0672daa461b0e70e1b73300cd65f7138d703aa80733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1478-3231.2006.01436.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1478-3231.2006.01436.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17355465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koskinas, J.</creatorcontrib><creatorcontrib>Kilidireas, C.</creatorcontrib><creatorcontrib>Karandreas, N.</creatorcontrib><creatorcontrib>Kountouras, D.</creatorcontrib><creatorcontrib>Savvas, S.</creatorcontrib><creatorcontrib>Hadziyannis, E.</creatorcontrib><creatorcontrib>Archimandritis, A.J.</creatorcontrib><title>Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background/Aims: Severe involvement of central and/or peripheral nervous system is a rare complication of hepatitis C virus (HCV)‐related cryoglobulinaemia.
Method: Four patients with HCV‐related type II/III cryoglobulinaemia (three males with genotype 1, one female with genotype 3) who presented with severe sensory–motor polyneuropathy, one with central nervous system involvement as well, were treated with pegylated IFNa‐2b 1.5 μg/kg/week and ribavirin 10.6 mg/kg/daily for 48 weeks. Neurological evaluation involved detailed clinical motor and sensory scores/scales and neurophysiological studies before and after treatment.
Results/Conclusion: Three out of four patients had undetectable serum HCV‐RNA, normal levels of aminotransferases and substantially lower or undetectable levels of cryoglobulins at the end of treatment and at 24 weeks follow‐up period. Treatment was well tolerated and all patients exhibited significant improvement of neuropathy based on solid clinical and laboratory criteria that was associated with the virological response.</description><subject>Adult</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Central Nervous System Diseases - virology</subject><subject>cryoglobulinaemia</subject><subject>Cryoglobulinemia - virology</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>HCV</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>pegylated interferon</subject><subject>peripheral neuropathy</subject><subject>Polyethylene Glycols</subject><subject>Polyneuropathies - diagnosis</subject><subject>Polyneuropathies - virology</subject><subject>Recombinant Proteins</subject><subject>ribavirin</subject><subject>Ribavirin - administration & dosage</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAURiMEoqXwCsgrVkyw48TOILFAI6CVRmLBz9ZynJsZj5w42E5b7_oISLxOn6ZPgjMZlS3e-Mo-37mLL8sQwTlJ590hJyWvV7SgJC8wZjkmJWX57ZPs_PHj6eNc0LPshfcHjMl6XZHn2RnhtKpKVp1n99_gGhygPYwy6KA92qBr7Sb_cPfbgZEBWqRctDtjm8noQUKvFfIweOviw92f3gbr0GhNHGByNkn2EQUHx-CNDns0wi4uHj0EcB04OyS5LBokhxY53ci0UA_vkUp-raR5i4xsrJPJHI_Mot5Hr62xuxlBPkxtfJk966Tx8Op0X2Q_Pn_6vrlcbb9-udp83K4UZZytqrJssWoKDFBA03YVqyVXmPGilbJkpMHAMZCGU4qxalnVcULrlmMqZY3T60X2ZvGOzv6awAfRa6_AGDmAnbzguGC0IusE1guonPXeQSdGp3vpoiBYzM2Jg5hLEXNBYm5OHJsTtyn6-rRjanpo_wVPVSXgwwLcaAPxv8Vie_VznuhfinexAg</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>Koskinas, J.</creator><creator>Kilidireas, C.</creator><creator>Karandreas, N.</creator><creator>Kountouras, D.</creator><creator>Savvas, S.</creator><creator>Hadziyannis, E.</creator><creator>Archimandritis, A.J.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200704</creationdate><title>Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study</title><author>Koskinas, J. ; Kilidireas, C. ; Karandreas, N. ; Kountouras, D. ; Savvas, S. ; Hadziyannis, E. ; Archimandritis, A.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3676-544d0cb20ee2ebdf568a7c0672daa461b0e70e1b73300cd65f7138d703aa80733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Central Nervous System Diseases - virology</topic><topic>cryoglobulinaemia</topic><topic>Cryoglobulinemia - virology</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>HCV</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>pegylated interferon</topic><topic>peripheral neuropathy</topic><topic>Polyethylene Glycols</topic><topic>Polyneuropathies - diagnosis</topic><topic>Polyneuropathies - virology</topic><topic>Recombinant Proteins</topic><topic>ribavirin</topic><topic>Ribavirin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koskinas, J.</creatorcontrib><creatorcontrib>Kilidireas, C.</creatorcontrib><creatorcontrib>Karandreas, N.</creatorcontrib><creatorcontrib>Kountouras, D.</creatorcontrib><creatorcontrib>Savvas, S.</creatorcontrib><creatorcontrib>Hadziyannis, E.</creatorcontrib><creatorcontrib>Archimandritis, A.J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koskinas, J.</au><au>Kilidireas, C.</au><au>Karandreas, N.</au><au>Kountouras, D.</au><au>Savvas, S.</au><au>Hadziyannis, E.</au><au>Archimandritis, A.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2007-04</date><risdate>2007</risdate><volume>27</volume><issue>3</issue><spage>414</spage><epage>420</epage><pages>414-420</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background/Aims: Severe involvement of central and/or peripheral nervous system is a rare complication of hepatitis C virus (HCV)‐related cryoglobulinaemia.
Method: Four patients with HCV‐related type II/III cryoglobulinaemia (three males with genotype 1, one female with genotype 3) who presented with severe sensory–motor polyneuropathy, one with central nervous system involvement as well, were treated with pegylated IFNa‐2b 1.5 μg/kg/week and ribavirin 10.6 mg/kg/daily for 48 weeks. Neurological evaluation involved detailed clinical motor and sensory scores/scales and neurophysiological studies before and after treatment.
Results/Conclusion: Three out of four patients had undetectable serum HCV‐RNA, normal levels of aminotransferases and substantially lower or undetectable levels of cryoglobulins at the end of treatment and at 24 weeks follow‐up period. Treatment was well tolerated and all patients exhibited significant improvement of neuropathy based on solid clinical and laboratory criteria that was associated with the virological response.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17355465</pmid><doi>10.1111/j.1478-3231.2006.01436.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2007-04, Vol.27 (3), p.414-420 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70263519 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Antiviral Agents - administration & dosage Central Nervous System Diseases - virology cryoglobulinaemia Cryoglobulinemia - virology Drug Therapy, Combination Female HCV Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Interferon-alpha - administration & dosage Male Middle Aged pegylated interferon peripheral neuropathy Polyethylene Glycols Polyneuropathies - diagnosis Polyneuropathies - virology Recombinant Proteins ribavirin Ribavirin - administration & dosage |
| title | Severe hepatitis C virus‐related cryoglobulinaemic sensory–motor polyneuropathy treated with pegylated interferon‐a2b and ribavirin: clinical, laboratory and neurophysiological study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A02%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20hepatitis%20C%20virus%E2%80%90related%20cryoglobulinaemic%20sensory%E2%80%93motor%20polyneuropathy%20treated%20with%20pegylated%20interferon%E2%80%90a2b%20and%20ribavirin:%20clinical,%20laboratory%20and%20neurophysiological%20study&rft.jtitle=Liver%20international&rft.au=Koskinas,%20J.&rft.date=2007-04&rft.volume=27&rft.issue=3&rft.spage=414&rft.epage=420&rft.pages=414-420&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2006.01436.x&rft_dat=%3Cproquest_cross%3E70263519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70263519&rft_id=info:pmid/17355465&rfr_iscdi=true |